Transdermal to Oral Estradiol Conversion
A transdermal patch delivering 0.075 mg/day estradiol is approximately equivalent to 2 mg oral micronized estradiol daily, though direct dose equivalence is imperfect due to different pharmacokinetic profiles.
Pharmacokinetic Rationale
The conversion is not straightforward because oral and transdermal estradiol have fundamentally different absorption and metabolism patterns:
Oral estradiol undergoes first-pass hepatic metabolism, resulting in 5-fold higher estrone levels and 10- to 20-fold higher estrone sulfate compared to transdermal administration at comparable doses 1
Transdermal estradiol bypasses hepatic first-pass metabolism, producing an estradiol-to-estrone ratio approximating 1:1 (similar to premenopausal physiology), whereas oral administration creates excessive estrone elevation 2
Evidence-Based Conversion
Research directly comparing these routes demonstrates:
A 0.05 mg/day transdermal patch produces steady-state estradiol levels of approximately 35 pg/mL with minimal fluctuation (0.65) 3
2 mg oral micronized estradiol produces average steady-state concentrations of 418 pg/mL with large fluctuations (3.68), but trough levels 24 hours post-dose are similar to transdermal steady-state levels 2, 3
The 0.075 mg transdermal dose in Turner syndrome patients produced estradiol levels of 114 ± 31 pg/mL, while 2 mg oral produced 46 ± 15 pg/mL (though measured at different time points) 4
Therefore, 0.075 mg transdermal roughly corresponds to 2 mg oral estradiol when considering clinical efficacy for symptom control and gonadotropin suppression, despite vastly different peak concentrations 2.
Clinical Considerations
Key Differences to Anticipate:
Metabolic effects differ: Oral estradiol increases SHBG, thyroid-binding globulin, triglycerides, and C-reactive protein due to hepatic first-pass effect 1
Thrombotic risk differs: Transdermal estradiol does not increase VTE risk even in high-risk women, while oral estradiol does (RR 2.07 for oral estrogen/progestin vs. 0.82 for transdermal) 5
Bioavailability varies: Oral estradiol has significantly higher bioavailability (61% higher) than transdermal gel formulations 6
When Converting:
- Start with 2 mg oral estradiol daily as the equivalent dose
- Titrate based on symptom response rather than strict dose equivalence 1
- Consider measuring estradiol levels if symptoms don't improve with escalating doses, particularly after route changes 1
- Expect different side effect profiles: oral may cause more nausea initially; transdermal may cause skin reactions
Important Caveats
There is no perfect 1:1 conversion because the routes produce different hormonal profiles. The 0.075 mg transdermal to 2 mg oral conversion is based on:
- Comparable gonadotropin suppression 2
- Similar clinical efficacy for vasomotor symptoms
- Trough oral levels approximating transdermal steady-state levels
However, oral administration exposes tissues to much higher peak estradiol and persistently elevated estrone metabolites 3. The clinical significance of these differences for long-term outcomes remains incompletely characterized, though cardiovascular and thrombotic safety clearly favor transdermal administration 1, 5.